Search





Search





Markets
/
Stocks
/
nasdaq-rare
/

Ultragenyx Pharmaceutical Inc

RARE

Add to Watchlist

26.400USD

-0.060-0.23%

Market hours （ET）Quotes delayed by 15 min

2.60BMarket Cap

LossP/E TTM



Ultragenyx Pharmaceutical Inc

26.400

-0.060-0.23%

Overview Financials Discussions Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Discussions

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Ultragenyx Pharmaceutical Inc

Currency: USD Updated: 2026-05-13

Key Insights

Ultragenyx Pharmaceutical Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 47 out of 156 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 51.68.In the medium term, the stock price is expected to trend up.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Ultragenyx Pharmaceutical Inc's Score

Industry at a Glance

Industry Ranking

47 / 156

Overall Ranking

132 / 4487

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Ultragenyx Pharmaceutical Inc Highlights

StrengthsRisks

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 54.98% year-on-year.

Overvalued

The company’s latest PE is -4.34, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 106.19M shares, decreasing 1.22% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 172.15K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.21.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

51.684

Target Price

+96.52%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-05-13

The current financial score of Ultragenyx Pharmaceutical Inc is 7.16, ranking 119 out of 156 in the Pharmaceuticals industry. Its financial status is weak, and its operating efficiency is average. Its latest quarterly revenue reached 136.00M, representing a year-over-year decrease of 2.36%, while its net profit experienced a year-over-year decrease of 22.45%.

Score

Industry at a Glance

Previous score

7.16

Change



Financials

5.36

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.64

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.60

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

7.94

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.26

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Ultragenyx Pharmaceutical Inc's Company Valuation

Currency: USD Updated: 2026-05-13

The current valuation score of Ultragenyx Pharmaceutical Inc is 6.12, ranking 131 out of 156 in the Pharmaceuticals industry. Its current P/E ratio is -4.34, which is -26.85% below the recent high of -3.17 and -109.69% above the recent low of -9.09.

Score

Industry at a Glance

Previous score

6.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 47/156

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-05-13

The current earnings forecast score of Ultragenyx Pharmaceutical Inc is 8.40, ranking 39 out of 156 in the Pharmaceuticals industry. The average price target is 78.50, with a high of 128.00 and a low of 35.00.

Score

Industry at a Glance

Previous score

8.40

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts

Buy

Current Rating

51.684

Target Price

+96.52%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Ultragenyx Pharmaceutical Inc

RARE

Amgen Inc

AMGN

Biogen Inc

BIIB

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

Vertex Pharmaceuticals Inc

VRTX

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-05-13

The current price momentum score of Ultragenyx Pharmaceutical Inc is 8.52, ranking 42 out of 156 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 28.02 and the support level at 24.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

8.90

Change

-0.38

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.231

Buy

RSI(14)

66.769

Neutral

STOCH(KDJ)(9,3,3)

72.683

Neutral

ATR(14)

1.088

High Vlolatility

CCI(14)

95.283

Neutral

Williams %R

25.703

Buy

TRIX(12,20)

0.557

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

26.370

Buy

MA10

25.706

Buy

MA20

25.062

Buy

MA50

23.050

Buy

MA100

23.780

Buy

MA200

27.676

Sell

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Ultragenyx Pharmaceutical Inc is 10.00, ranking 1 out of 156 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 107.82%, representing a quarter-over-quarter increase of 3.72%. The largest institutional shareholder is Frank Sands, holding a total of 3.21M shares, representing 3.26% of shares outstanding, with 25.89% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

5.07M

+1.09%

State Street Investment Management (US)

3.69M

+43.55%

Sands Capital Management, LLC

Star Investors

3.77M

-4.40%

JP Morgan Asset Management

3.25M

+24.74%

RTW Investments L.P.

3.26M

+90.83%

Kakkis (Emil D)

2.69M

-1.17%

Baker Bros. Advisors LP

2.77M

Wellington Management Company, LLP

1.95M

+3.92%

Risk Assessment

Currency: USD Updated: 2026-05-13

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Ultragenyx Pharmaceutical Inc is 3.64, ranking 100 out of 156 in the Pharmaceuticals industry. The company's beta value is 0.38. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.